Choosing the right treatment for type 2 diabetes or weight management means balancing your blood sugar goals and target weight with side effects and long-term health outcomes. While newer medications like tirzepatide have quickly become among the most widely prescribed options by doctors, older medications like exenatide still play a role in care (and are still sometimes prescribed off-label for weight management).

If you’re juggling midlife health shifts, you want straightforward answers. Read on as we compare tirzepatide versus exenatide, covering how each works, plus key study outcomes and risks to consider. 

‍

What are tirzepatide and exenatide?

Tirzepatide and exenatide are both glucagon-like peptide-1 receptor agonists (GLP-1 RAs), meaning they mimic a hormone our bodies naturally produce called glucagon-like peptide-1 (GLP-1). GLP-1 works through several pathways, including:

• Insulin secretion prompts your pancreas to produce and release insulin, but only when your blood sugar (glucose) levels rise. Once your blood sugar returns to a normal range, the signal stops. Over time, keeping these glucose levels stable directly lowers your A1c, a standard clinical test that measures your average blood sugar over the previous three months.
• Glucagon suppression limits glucagon, a hormone that tells the liver to release stored glucose between meals. In a healthy metabolic state, glucagon drops after you eat. But in people with type 2 diabetes, the liver often keeps pumping out glucagon post-meal, dumping extra sugar into the bloodstream. GLP-1 suppresses this release, stopping your liver from adding extra sugar on top of the meal you just digested and preventing post-meal blood sugar spikes.
• Gastric emptying signals the muscles in your stomach to relax and slow down. Because food leaves the stomach at a slower and steadier rate, sugar from your meal enters your bloodstream gradually over a longer period rather than all at once. This prevents post-meal blood sugar spikes and keeps you feeling fuller for longer. 
• Satiety acts on the appetite center of the brain (hypothalamus), dampening hunger signals and prolonging feelings of fullness. This helps reduce the urge to keep eating.

What’s the difference between tirzepatide and exenatide?

Unlike exenatide, which only mimics GLP-1, tirzepatide is a dual agonist. It also mimics a second hormone called glucose-dependent insulinotropic polypeptide (GIP). 

While your intestines release both GLP-1 and GIP after you eat to stimulate your pancreas to release insulin, these hormones have different secondary roles in your body. GLP-1 works in the ways described above. GIP, however, plays a more direct role in how your body processes and stores fat (triglycerides) circulating in the blood. It binds directly to receptors on fat (adipose) tissue, enhancing blood flow to fat cells, stimulating local nutrient uptake, and promoting the clearance of fats from the bloodstream. 

GIP receptors are found in both under-the-skin (subcutaneous) fat and the fat that surrounds deep internal organs (visceral fat). In a healthy state, GIP directs incoming dietary lipids into subcutaneous adipose tissue to store extra energy. During midlife and menopause, declining estrogen levels often impair the body’s ability to store fat safely in subcutaneous areas, forcing it to spill over into dangerous visceral fat. 

‍

What are tirzepatide and exenatide FDA-approved for?

Here’s what the FDA approves each medication to treat.

Exenatide (Generic, previously Byetta® and Byduron®)

The FDA approved the first GLP-1 RA medication, exenatide (Byetta®) in 2005 to treat type 2 diabetes. In 2012, the FDA approved a longer-lasting version of the drug, Bydureon®.

AstraZeneca discontinued both brand-name drugs Byetta® and Bydureon® in late 2024. This was the result of business-related decisions, not safety or efficacy concerns. While the brand name versions are gone, a generic version of exenatide launched in 2025 following a 2024 FDA approval.

Tirzepatide (Mounjaro® and Zepbound®)

Tirzepatide is a dual GLP-1/GIP receptor agonist manufactured by Eli Lilly under two brand names: Mounjaro® and Zepbound®. The FDA approved Mounjaro® in 2022 to treat type 2 diabetes. It then approved Zepbound® in 2023 for chronic weight management. In 2024, the FDA also approved Zepbound® to treat moderate-to-severe obstructive sleep apnea (OSA).

‍

Tirzepatide vs. exenatide at a glance

Here are the main similarities and differences between tirzepatide (Mounjaro® and Zepbound®) and exenatide: 

*Costs and coverage vary with insurance plans and savings programs

What does the research show? 

The FDA approves both tirzepatide and exenatide to treat type 2 diabetes. However, clinical data show that tirzepatide delivers stronger outcomes than exenatide:

• Tirzepatide: In the phase 3 SURPASS-1 trial, adults with type 2 diabetes lowered their A1c by up to 2.07%. Up to 52% of participants on the highest dose achieved normal, non-diabetic A1c levels (below 5.7%). Elevated A1c levels include 6.5% or higher.
• Exenatide: Older trials, like a 2008 study in Clinical Therapeutics, show more modest outcomes for exenatide. Participants reduced A1c by 0.7–0.9%.
• Direct comparison: Head-to-head research, including a meta-analysis published in Diabetes Therapy, confirms that tirzepatide outperforms exenatide. Tirzepatide achieves a greater reduction in blood sugar.

Beyond type 2 diabetes: Weight loss outcomes

Both medications can impact weight. However, clinical trial results for non-diabetic adults with obesity (or with a BMI over 27 and a weight-related condition like high blood pressure) show a clear difference in scale:

• Tirzepatide: The SURMOUNT-1 trial evaluated 2,539 adults. On the highest dose (15 mg), participants lost an average of approximately 21% of their body weight, compared to 3% for the placebo group. This study meaningfully contributed to Zepbound’s® FDA-approved status for chronic weight management.
• Exenatide: A 2010 Diabetes Care study assessed adults over 24 weeks. While the FDA doesn’t approve this medication for weight loss, participants still achieved measurable results. Patients lost an average of 4.7% of their body weight (about 11 pounds).

‍

Common side effects

For both tirzepatide and exenatide, gastrointestinal (GI) side effects are most common. Because both medications slow down the rate that food leaves your stomach and change metabolic signaling, they commonly trigger adverse events like:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort or bloating

These issues are typically dose-dependent, meaning they’re most likely to appear when starting the medication for the first time or when stepping up to a higher dose. For most people, symptoms gradually improve over time as the body adjusts.

‍

Other risks and safety concerns

Beyond common side effects, there are several safety factors to review with your healthcare provider before starting treatment:

• Compounded versions: Compounding pharmacies create these custom-mixed alternatives to branded medications. They may (but don’t always) contain active ingredients like tirzepatide or exenatide, but these formulations aren’t FDA-approved. This means they don’t undergo rigorous federal evaluations for safety, manufacturing consistency, and efficacy.
• Contraindications: Your doctor will evaluate your personal family medical history to ensure you don’t have preexisting conditions these medications could exacerbate. Disqualifying conditions include medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Adverse events: Rare but serious medical complications like pancreatitis or gallbladder disease can develop during treatment, even in patients with no prior risk factors. Your doctor will proactively monitor your progress to identify early signs of potential complications.

‍

Can I switch from exenatide to tirzepatide? 

It’s possible to switch from exenatide to tirzepatide, but consult your doctor before making any changes to your medications. Because these drugs have different potencies and dosing schedules, a direct swap may cause digestive upset or blood sugar disruption. 

If your doctor deems a switch appropriate, they’ll guide you through a structured transition from one medication to the other. This usually involves safely tapering off exenatide. Once finished, you’ll likely initiate tirzepatide at its lowest starting dose during your usual injection time to allow your body to adjust.

‍

Get supported GLP-1 care with Maven Clinic

Choosing between a single-agonist like exenatide and a dual-agonist like tirzepatide can feel overwhelming. And navigating how these medications impact your metabolic health and long-term goals requires ongoing, comprehensive support. 

At Maven Clinic, our specialists integrate GLP-1 care into a broader clinical model designed around women’s health. This includes expert medical oversight, personalized nutritional guidance, and continuous side effect management—all built around how your body works.

That’s why millions of women trust us with their health. Discover our approach to GLP-1 care.